Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19 (preprint)

Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Julia Stowe; Elise Tessier; Ruth Simmons; Mary Ramsay

This article is a Preprint

Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.

Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19 (preprint)

Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Julia Stowe; Elise Tessier; Ruth Simmons; Mary Ramsay.

medrxiv; 2021.

Preprint in English | medRxiv | ID: ppzbmed-10.1101.2021.05.14.21257218

ABSTRACT

ABSTRACT

We estimated risk of death in vaccinated compared to unvaccinated COVID-19 cases. Cases vaccinated with 1 dose of BNT162b2 had 44% reduced risk of death, 55% with 1 dose of ChAdOx1, and 69% with 2 doses of BNT162b2. This is on top of the protection provided against becoming a case.

Fulltext

XML

Search on Google

Full text: Available Collection: Preprints Database: medRxiv Language: English Year: 2021 Document Type: Preprint

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google

Full text: Available Collection: Preprints Database: medRxiv Language: English Year: 2021 Document Type: Preprint